Studies have shown that active fund managers routinely underperform the S&P500 index*​

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN)

NRSN Stock Predictions and Ratings

WSX Rating:
NOT AVAILABLE
WSX Forecast (1yr):
NOT AVAILABLE
Analyst Rating:
STRONG BUY
Analyst Forecast (1yr):
400%

NRSN Stock Analysis

NRSN PE Ratio:

NRSN PEG Ratio: Not Available

NRSN Forward EPS Growth (12 month): 0.00%

NRSN PS Ratio:

NRSN PSG Ratio:

NRSN Forward Revenue Growth (12 month): 400.00%

NRSN Articles

No data was found